Загрузка...
Clostridioides difficile-induced diarrhoea following dasatinib therapy
Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However, Clostridioides difficile infections (CDIs) in the context of dasatinib therapy, without a...
Сохранить в:
| Опубликовано в: : | BMJ Case Rep |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7813327/ https://ncbi.nlm.nih.gov/pubmed/33462050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-239394 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|